|
[Objective] CD133, CD44 ~ / CD24 ~ -, CD44 ~ -/CD24 ~ in breast cancer occur in different stages (benign breast hyperplasia, atypical hyperplasia, breast carcinoma in situ, breast cancer), the expression of differences, its expression with breast cancer between clinicopathological factors and the analysis of the correlation between the expression of CD133 and CD44 ~~ / CD24 -, CD44 -/CD24 ~. [] Collection Kunming General Hospital of Chengdu Military Region, 45 cases of normal breast tissue, 41 cases of benign proliferative breast tissue, breast tissue of 39 cases of atypical hyperplasia, 51 cases of breast carcinoma in situ, 121 cases of breast cancer detected by immunohistochemical CD133 CD133, CD44 ~ / CD24 ~ -, CD44 ~ -/CD24 ~ occurs in breast cancer at different stages (benign breast hyperplasia, atypical hyperplasia, breast carcinoma in situ, breast cancer and CD44/CD24 double staining expression, analysis relationship between) expression differences and expression in breast cancer and breast cancer in all clinical pathological factors, and analysis CD133 and CD44 ~~ / CD24 ~ - expressed in between of CD44 ~ -/CD24 ~~ have the relevant sex. [Results] 1, CD133 expression in cytoplasm. Not express CD133 in normal breast tissue, CD133 in benign hyperplasia, atypical hyperplasia, breast carcinoma in situ, the expression rate of breast cancer were 31.7%, 48.7%, 64.8%, 74.4%, the difference was statistically significant difference (P lt; 0.01). 2, CD133 Ⅰ, Ⅱ grade class III breast cancer tissue positive expression rates were 63.6% (21/33), 72.7% (26/36), 82.7% (43/52) have each classification significant difference (P lt; 0.05). CD133 Ⅳ of breast tissue positive expression rate was 94.3% (33/35), significantly higher than the positive expression rate of Ⅰ breast cancer (57.1%, 12/21) and II breast cancer, the positive expression rate ( 69.4%, 34/49) and Ⅲ breast cancer positive expression rate (68.7%, 11/16) between the two groups there is a statistically significant difference (P lt; 0.01). CD133 positive expression rate was 82.0% (41/50) in lymph node metastasis in breast cancer tissue without lymph node metastasis of CD133 positive expression rate was 69.0% (49/71) (P lt; 0.05). Distant metastasis of CD133 expression was significantly higher than the positive expression rate of distant metastasis, former expression was 94.3% (33/35), whose expression was 66.3% (57/86) The comparison between the two statistically significant difference (P <0.01). CD133 positive expression of a recurrence of breast cancer patients was 82.8% (53/64), no the recurrence expression was 64.9% (37/57) (P <0.05). Kaplan-Meier survival curves show the CD133 positive patients overall survival and recurrence-free survival rate of less than negative patients (P <0.05). Cox proportional hazards regression model confirmed CD133 do not do as an independent prognostic indicator (P> 0.05). CD133 positive expression rate in breast cancer patients with the patient's age, menopausal status, tumor histological type, tumor size, ER, PR, Her-2 expression was no significant correlation (P> 0.05). 3, CD44 ~ -/CD24 ~ in small amounts in normal breast tissue expression ≤ 10% of which 96.6% (14/15) of cases the percentage of positive cells major myoepithelial express. CD44 ~ -/CD24 ~ benign breast hyperplasia, atypical hyperplasia, breast carcinoma in situ, breast cancer and 43.9% (18/41), 53.8% (21/39), 68.6% (35/51 ), 86% (104/121), the difference was statistically significant (P <0.01). 4, CD44 ~ -/CD24 ~ Ⅰ, Ⅱ grade class III breast cancer tissue positive expression rate was 78.8% (25/33), 88.9% (32/36), 88.5% (48/52) ( P = 0.006), with significant statistical significance. The CD44 ~ -/CD24 ~ Ⅰ, Ⅱ period, phase III IV breast cancer organization in the positive expression rate was 76.2% (16/21), 85.7% (41/49), 87.5% (14/16 ), 91.4% (32/35) (P <0.01). Distant metastasis by the CD44 ~ -/CD24 ~ positive expression rate was higher than the rate of positive expression without distant metastasis, the expression of the former was 91.4% (32/35), the latter expression was 83.7% ( 72/86), a statistically significant difference (P = 0.000) in the comparison between the two. Its recurrence in breast cancer patients of CD44 ~ -/CD24 ~ of positive expression rate was 90.6% (58/64), the the recurrence expression rate was 80.7% (46/57) P <0.05). Kaplan-Meier survival curve shows the the CD44 ~ -/CD24 ~ positive patients, overall survival and relapse-free survival time and its negative patients ask no difference (P> 0.05). Cox proportional hazards regression model confirmed CD44 ~ -/CD24 ~ can not be used as an independent prognostic indicator (P> 0.05). CD44 ~ -/CD24 ~ positive expression rate in breast cancer patients with the patient's age, menopausal status, tumor histological type, tumor size, ER, PR, Her-2 expression was no significant correlation (P> 0.05). 5, CD44 ~ / CD24 ~ - in small amounts in normal breast tissue expression, its expression was 20% (9/45). CD44 ~ -/CD24 ~ - benign breast hyperplasia, atypical hyperplasia, DCIS, breast cancer and 29.3% (12/41), 35.9% (14/39), 43.1% (22 / 51), 52.9% (64/121), the difference was statistically significant (P <0.05). 6, breast cancer cells of CD44 ~ / CD24 ~ - mainly expressed in the cell membrane, the expression of patients with lymph node metastasis was 64% (32/50), the expression of lymph node metastasis in patients was 43.7% (31/71) (P <0.05). Expression rate and patient age, menopausal status, tumor histological type, histological grade, TNM stage, tumor size, blood metastasis, ER, PR, Her-2 expression was no significant correlation (P> 0.05). Kaplan-Meier survival curves show no difference (P> 0.05) between the CD44 ~ -/CD24 ~ positive patients, overall survival and recurrence-free survival of patients with negative. Cox multivariate hazards regression model confirmed CD44 ~ / CD24 ~ - not as an independent prognostic indicator (P> 0.05). 7 in benign breast hyperplasia, atypical hyperplasia, the expression of CD133 and CD44 ~ -/CD24 ~ and the expression of CD44 ~ / CD24 ~ - are not a correlation (P> 0.05). CD133 expression and the expression of CD44 ~ / CD24 ~ - in breast carcinoma in situ and invasive breast cancer, no correlation (P> 0.05). CD133 expression in breast carcinoma in situ expression of CD44 ~ -/CD24 ~ correlation (γ = 0.408, P = 0.003); 121 cases of invasive breast cancer in 67% of breast cancer specimens (81/121) The co-expression of CD133 and CD44 ~ -/CD24 ~, With the increase of the expression of CD133, CD44 -/CD24 ~~ positive rate gradually improve. CD133 and CD44 ~ -/CD24 ~ expression in breast cancer tissue positive correlation (γ = 0.217, P = 0.017) [Conclusion] 1, CD133 expressed in normal breast tissue, of CD44 ~ -/CD24 ~~, CD44 ~ / CD24 ~ - little expression in normal breast tissue. 2, CD133, CD44 ~ -/CD24 ~, CD44 ~ / CD24 ~ - in benign breast hyperplasia, atypical hyperplasia, breast carcinoma in situ breast cancer and the difference was statistically significant (P <0.05). Excessive 3.CD133 expression in breast cancer, and its overexpression with tumor pathological grade, TNM stage, lymph node metastasis, distant metastasis, patients relapse, relapse-free survival time, a statistically significant overall survival time between significance (P <0.05), and the patient's age, menopausal status, tumor size, ER, PR, Her-2, no significant correlation (P> 0.05). CD133 can not be used as an independent indicator of prognosis. 4, CD44 ~ -/CD24 ~ expression in breast cancer tissue and pathological grading, TNM stage, lymph node metastasis, distant metastasis, statistically significant (P <0.01) between patients relapse, and the patient's age, menstrual status, tumor size, recurrence-free survival time, overall survival, ER, PR, Her-2 was no significant correlation (P> 0.05). CD44 ~ -/CD24 ~ can not be used as an independent indicator of prognosis. Breast cancer cells CD44 ~ / CD24 ~ - mainly expressed in the cell membrane, expression in patients with lymph node metastasis, the expression rate higher than in patients without lymph node metastasis, a significant difference (P <0.05) between the two. Expression rate and patient age, menopausal status, tumor histological type, histological grade, TNM stage, tumor size, blood metastasis patients relapse, relapse-free survival time and overall survival time of ER, PR, Her-2 expression was no significant correlation (P> 0.05). 6, CD133 and CD44 ~ -/CD24 ~ expression in breast carcinoma in situ and breast cancer in correlation (P <0.05).
|